Zehn Jahre Neuroethik des pharmazeutischen kognitiven Enhancements – Aktuelle Probleme und Handlungsrichtlinien für die Praxis

 

 Buy Article Permissions and Reprints

Zusammenfassung

Ein auswertender Überblick über die Entwicklung der Neuroethik des pharmazeutischen kognitiven Enhancements (PCE) innerhalb der letzten zehn Jahre, mit einem Schwerpunkt auf der Situation in der Bundesrepublik Deutschland. Der Artikel benennt die wichtigsten begrifflichen Probleme, aktuelle Substanzen und zentrale ethisch-juristische Fragestellungen; am Ende werden allererste Handlungsrichtlinien und Empfehlungen für die Politikgestaltung formuliert.

Abstract

An evaluating survey of the development of the neuroethics of pharmaceutical cognitive enhancement (PCE) during the last decade, focussing on the situation in Germany, has been undertaken. This article presents the most important conceptual problems, current substances and central ethical and legal issues. Very first guidelines and recommendations for policy-makers are formulated at the end of the text.

• Literatur

• 1 Illes J, Sahakian BJ. The Oxford Handbook of Neuroethics. New York: Oxford University Press; 2011
  Google Scholar
• 2 Marcus SJ (ed.) Neuroethics: Mapping the Field. New York: The Dana Press; 2002
  Google Scholar
• 3 Farah M. Neuroscience and neuroethics in the 21st centruy. In: Illes J, Sahakian BJ. The Oxford Handbook of Neuroethics. New York: Oxford University Press; 2011: 761-781
  Google Scholar
• 4 Metzinger T, Hildt E. Cognitive enhancement. In: Illes J, Sahakian BJ. The Oxford Handbook of Neuroethics. New York: Oxford University Press; 2011: 245-264
  Google Scholar
• 5 Morein-Zamir S, Sahakian B. Pharmaceutical cognitive enhancement. In: Illes J, Sahakian BJ. The Oxford Handbook of Neuroethics. New York: Oxford University Press; 2011: 229-244
  Google Scholar
• 6 Sahakian B, Morein-Zamir S. Neuorethical issues in cognitive enhancement. J Psychopharm 2011; 25 (02) 197-204
  CrossrefPubMedGoogle Scholar
• 7 Glannon W. Psychopharmacological enhancement. Neuroethics 2008; 1: 45-54
  CrossrefPubMedGoogle Scholar
• 8 De Jongh R, Bolt I, Schermer M et al. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev 2008; 32: 760-776
  CrossrefPubMedGoogle Scholar
• 9 Mehlman MJ. Cognition-enhancing drugs. Milbank Quart 2004; 82 (03) 483-506
  CrossrefPubMedGoogle Scholar
• 10 Larriviere D, Williams MA, Rizzo M et al. Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Neurol 2009; 73 (17) 1406-1412
  CrossrefPubMedGoogle Scholar
• 11 Lieb K. Hirndoping. Mannheim: Tamtmos, Artemis & Winkler; 2010
  Google Scholar
• 12 Schöne-Seifert B, Talbot D (Hrsg) Enhancement. Die ethische Debatte. Paderborn: mentis; 2009
  Google Scholar
• 13 Förstl H. Neuro-Enhancement – Gehirndoping. Der Nervenarzt 2009; 7: 840-845
  PubMedGoogle Scholar
• 14 Hoy KE, Fitzgerald PB. Brain stimulation in psychiatry and its effects on cognition. Nat Rev Neurol 2010; 6: 267-275
  CrossrefPubMedGoogle Scholar
• 15 Kramer PD. Listening to Prozac. A Psychiatrist Explores Antidepressant Drugs and the Remaking of the Self. Viking Press; 1993
  Google Scholar
• 16 Cerullo MA. Cosmetic psychopharmacology and the President’s Council on Bioethics. Persp Biol Med 2006; 49 (04) 515-523
  CrossrefPubMedGoogle Scholar
• 17 Clark A, Chalmers DJ. Der erweiterte Geist. In: Metzinger T, (Hrsg) Grundkurs Philosophie des Geistes. Band III: Intentionalität und mentale Repräsentation.
  Google Scholar
• 18 Menary R (Hrsg) The Extended Mind. Cambridge: MA: MIT Press; 2010
  Google Scholar
• 19 Buller T. Neurotechnology, invasiveness and the extended mind. Neuroethics 2011; DOI: 10.1007/s12152-011-9133-9135.
  PubMedGoogle Scholar
• 20 Schermer M, Bolt I, de Jongh R et al. The future of psychopharmacological enhancements: expectations and policies. Neuroethics 2009; 2: 75-87
  CrossrefPubMedGoogle Scholar
• 21 Outram SM. Ethical considerations in the framing of the cognitive enhancement debate. Neuroethics 2011; DOI: 10.1007/s12152-011-9131-7.
  PubMedGoogle Scholar
• 22 Jüngst ET. What does enhancement mean?. In: Parens E, (ed.) Enhancing human traits: ethical and social implications. Washington D.C: Georgetown University Press; 1998: 29-47
  Google Scholar
• 23 Harris J. Enhancing Evolution. Princeton: Princeton University Press; 2007
  Google Scholar
• 24 Greely H, Sahakian B, Harris J et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008; 456: 702-705
  Google Scholar
• 25 Daniels N. Normal functioning and the treatment-enhancement distinction. Camb Quart Health Eth 2000; 9: 309-322
  PubMedGoogle Scholar
• 26 Synofzik M. Ethically justified, clinically applicable criteria for physician decision-making in psychopharmacological enhancement. Neuroethics 2009; 2: 89-102
  Google Scholar
• 27 Murphy D. Concepts of disease and health. In: Zalta EN, (ed.) The Stanford Encyclopedia of Philosophy.(Fall 2009 edition). http://plato.stanford.edu/archives/sum2009/entries/health-disease/ [Epub only]
  Google Scholar
• 28 Kutschenko L. In quest of “good” medical classification systems. Med Stud 2011; 3 (1): 53-70
  PubMedGoogle Scholar
• 29 Birnbacher D. Bioethik zwischen Natur und Interesse. Frankfurt: Suhrkamp; 2006
  Google Scholar
• 30 Birnbacher D. Analytische Einführung in die Ethik. 2. . Aufl. Berlin: de Gruyter; 2007
  CrossrefGoogle Scholar
• 31 Gather J. The evaluation of psychopharmacological enhancers beyond a normative “natural”-“artificial” dichtomoy. Med Stud 2011; 3 (1): 19-27
  PubMedGoogle Scholar
• 32 Krämer F. Authenticity anyone? The enhancement of emotions via neuro-psychopharmacology. Neuroethics 2011; 4: 51-64
  CrossrefPubMedGoogle Scholar
• 33 Singh I. Beyond polemics: science and ethics of ADHD. Nat Rev Neur 2008; 9: 957-964
  PubMedGoogle Scholar
• 34 Wilens TE, Adler LA, Adams J et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47 (01) 21-31
  Google Scholar
• 35 Low KG, Gendaszek AE. Illicit use of stimulants among college students: A preliminary study. Psych Hea & Med 2002; 7: 283-287
  PubMedGoogle Scholar
• 36 Forlini C, Racine E. Autonomy and coercion in academic “Cognitive Enhancement” using methylphenidate: perspectives of key stakeholders. Neuroethics 2009; 2: 163-177
  CrossrefPubMedGoogle Scholar
• 37 Repantis D, Schlattmann P, Laisney O et al. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res 2010; 62 (03) 187-210
  Google Scholar
• 38 Repantis D. Die Wirkung von Psychopharmaka bei Gesunden. In: Wienke A, Eberbach WH, Kramer HJ, Janke K, (Hrsg) Die Verbesserung des Menschen: Tatsächliche und rechtliche Aspekte der wunscherfüllenden Medizin. Heidelberg: Springer; 2009: 63-68
  Google Scholar
• 39 Franke AG, Bonertz C, Christmann M et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011; 43: 1-7
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Franke AG, Konrad A, Lieb K et al. Psychostimulantien und Nicht-Stimulantien in der heutigen und zukünftigen ADHS-Therapie. Fortschr Neurol Psychiat 2011; 79: 1-11
  PubMedGoogle Scholar
• 41 Singh I, Kelleher KJ. Neuroenhancement in Young People: Proposal for Research, Policy, and Clinical Management.  AJOB Neuroscience 2010; 1 (01) 3-16
  PubMedGoogle Scholar
• 42 Singh I, Kendall T, Taylor C et al. Young people’s experience of ADHD and stimulant medication: A qualitative study for the NIC guideline. Child Adol Ment Health 2010; 15 (04) 186-192
  PubMedGoogle Scholar
• 43 Singh I. A disorder of anger and aggression: Children’s perspectives on attention deficit/hyperactivity disorder in the UK. Soc Scie & Med 2011; 73 (06) 889-896
  PubMedGoogle Scholar
• 44 Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008; 33 (07) 1477-1502
  Google Scholar
• 45 Repantis D, Laisney O, Heuser I et al. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res 2010; 61 (06) 473-481
  Google Scholar
• 46 Repantis D, Schlattmann P, Laisney O et al. Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis & Praxis 2009; 6 (03) 139-174
  CrossrefPubMedGoogle Scholar
• 47 Slingsby B. The Prozac boom and its placebogenic counterpart – a culturally fashioned phenomenon. Med Sci Monit 2002; 8 (05) CR389-CR393
  PubMedGoogle Scholar
• 48 DAK (Deutsche Angestellten-Krankenkasse). Gesundheitsreport 2009. Analyse der Arbeitsunfähigkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz. Berlin: 2009 http://www.dak.de/content/filesopen/Gesundheitsreport_2009.pdf
  PubMedGoogle Scholar
• 49 McCabe SE, Knight JR, Teter CJ et al. Non-medical use of prescriptions stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005; 100 (01) 96-106
  CrossrefPubMedGoogle Scholar
• 50 Franke A, Lieb K. Pharmakologisches Neuroenhancement und „Hirndoping”: Chancen und Risiken. Bundesgesundheitsbl 2010; 53: 853-858
  CrossrefPubMedGoogle Scholar
• 51 Maher B. Poll results: look who's doping. Nature 2008; 452: 674-675
  Google Scholar
• 52 Sahakian BJ, Morein-Zamir S. Professor’s little helper. Nature 2007; 450: 1157-1159
  CrossrefPubMedGoogle Scholar
• 53 Schleim S, Walter H. Cognitive Enhancement – Fakten und Mythen. Nervenheilkunde 2007; 26: 83-87
  PubMedGoogle Scholar
• 54 Galert T, Bublitz C, Heuser I et al. Das optimierte Gehirn. Ein Memorandum zu Chancen und Risiken des Neuroenhancements. Gehirn & Geist 2009; 11:  40-48
  PubMedGoogle Scholar
• 55 Douglas T. Moral enhancement. J Appl Philos 2008; 25: 228-245
  CrossrefPubMedGoogle Scholar
• 56 Harris J. Moral enhancement and freedom. Bioethics 2011; 25 (02) 102-111
  CrossrefPubMedGoogle Scholar
• 57 Persson I, Savulescu J. The perils of cognitive enhancement and the urgent imperative to enhance the moral character of humanity. J Appl Philos 2008; 25: 162-177
  CrossrefPubMedGoogle Scholar
• 58 Fröding BEE. Cognitive enhancement, virtue ethics and the good life. Neuroethics 2011; 4: 223-234
  CrossrefPubMedGoogle Scholar
• 59 Moynihan R, Doran E, Henry D. Disease mongering is now part of the global health debate. PLoS Med 2008; 5 (05) e106 DOI: 10.1371/journal.pmed.0050106.
  CrossrefPubMedGoogle Scholar
• 60 Public Library of Science. A collection of articles on disease mongering. PLoS Med 2008; 3 (04) e191 DOI: 10.1371/journal.pmed.0030191. http://collections.plos.org/plosmedicine/diseasemongering-2006.php
  PubMedGoogle Scholar
• 61 Davis K. Rethinking „normal”. Hast Cen Rep 2007; 37 (03) 44-47
  PubMedGoogle Scholar
• 62 Metzinger T. The no-self-alternative (Chapter 11). In: Gallagher S, (ed.) The Oxford Handbook of the Self. Oxford: Oxford University Press; 2011: 279-296
  CrossrefGoogle Scholar
• 63 Metzinger T. Der Ego-Tunnel. Berlin: Bloomsbury; 2011
  Google Scholar
• 64 Metzinger T. Why are identity-disorders interesting for philosophers?. In: Schramme T, Thome J, (eds.) Philosophy and Psychiatry. Berlin: de Gruyter; 2004: 311-325
  CrossrefGoogle Scholar
• 65 Metzinger T. Being No One. The Self-Model Theory of Subjectivity. Cambridge: MIT Press; 2003
  Google Scholar
• 66 Bolt I, Schermer M. Psychopharmaceutical enhancers: enhancing identity?. Neuroethics 2008; 2: 103-111
  PubMedGoogle Scholar
• 67 Olson ET. Personal identity. In: Zalta EN, (ed.) The Stanford Encyclopedia of Philosophy.(Winter 2010 Edition). http://plato.stanford.edu/archives/win2010/entries/identity-personal/ [Epub only]
  Google Scholar
• 68 Shoemaker D. Personal identity and ethics. In: Zalta EN, (ed.) The Stanford Encyclopedia of Philosophy.(Winter 2010 Edition). http://plato.stanford.edu/archives/fall2008/entries/identity-ethics/ [Epub only]
  Google Scholar
• 69 DeGrazia D. Human Identity and Bioethics. Cambridge: Cambridge University Press; 2005
  CrossrefGoogle Scholar
• 70 Galert T. Wie mag Neuro-Enhancement Personen verändern?. In: Schöne-Seifert B, Talbot D, Opolka U, Ach JS, (Hrsg) Neuro-Enhancement. Ethik vor neuen Herausforderungen. Paderborn: mentis; 2008: 159-187
  Google Scholar
• 71 Gillett G. Subjectivity and Being Somebody: Human Identity and Neuroethics. Exeter: Imprint; 2008
  Google Scholar
• 72 Merkel R, Boer R, Fegert J et al. Intervening in the brain – Changing Psyche and Society. Berlin: Springer; 2007
  Google Scholar
• 73 Bublitz JC, Merkel R. Autonomy and authenticity of enhanced personality traits. Bioethics 2009; 23 (06) 360-374
  CrossrefPubMedGoogle Scholar
• 74 Califano J. “You’ve got drugs!” Prescription drug pushers on the internet. New York: Columbia University: The National Center on Addiction and Substance Abuse; 2008: 1-15
  Google Scholar
• 75 Sententia W. Neuroethical considerations: Cognitive liberty and converging technologies for improving human cognition. Ann N Y Acad Sci 2004; 1013: 221-228
  PubMedGoogle Scholar
• 76 Capps B. Libertarianism, legitimation, and the problems of regulating cognition-enhancing drugs. Neuroethics 2011; 4: 119-128
  CrossrefPubMedGoogle Scholar
• 77 Nagel SK. Too much of a good thing? Enhancement and the burden of self-determination. Neuroethics 2010; 3: 109-119
  CrossrefPubMedGoogle Scholar
• 78 Nagel SK. Ethics and the Neurosciences: Ethical and Social Consequences of Neuroscientific Progress. Paderborn: mentis; 2010
  Google Scholar